

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

NCT06853665

Status	RECRUITING
Phase	Phase 4
Sponsor	Gagan Joshi
Enrollment	196 participants

Key Eligibility Criteria

Inclusion (17)

- Participants with Autism Spectrum Disorder (ASD) and Attention Deficit/Hyperactivity Disorder (ADHD)
- Male or female participants between 8 and 18 years of age (inclusive).
- Participant intact communicative language, as clinically determined.
- Meet DSM-5-TR diagnoses of ADHD and ASD as established by clinical diagnostic interview.
- At least moderate current ADHD symptoms severity (Clinician-rated ADHD-RS score e28 and ADHD-CGI-S of e4)

... and 12 more (see full listing online)

Exclusion (27)

- Impaired intellectual capacity as determined either by history of intellectual disability or as assessed, in ASD participants only, during the clinical evaluation and determination will be based on intact communicative language, intellectual performance, and ability to take personal care.
- Participant is unable to communicate due to delay in, or total lack of, spoken language development (grossly impaired language skills)
- Participants with a poor command of the English language and/or require an interpreter.
- Participant is unable to swallow pills (ASD participants only)
- Participants with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study, including:

... and 22 more (see full listing online)

Locations (1 total)

Massachusetts General Hospital, Boston, Massachusetts, United States